Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 3 , Pages 271-275 , May 2009

Maximizing the Alzheimer's Disease Neuroimaging Initiative II

  • Maria C. Carrillo

      Affiliations

    • Alzheimer's Association, Chicago, IL, USA
    • Corresponding Author InformationCorresponding author. Tel.: 312-335-5722.
    • ,
  • Charles A. Sanders

      Affiliations

    • Foundation for the National Institutes of Health, Bethesda, MD, USA
    • ,
  • Russell G. Katz

      Affiliations

    • United States Food and Drug Administration, Washington, DC, USA

References 

  1. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005;1:55–66
  2. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  3. Jack CR, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for Alzheimer's. Neurology. 2003;60:253–260
  4. Jack CR, Shiung MM, Gunter JL, O'Brien PC, Weigand SG, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591–600
  5. Langbaum JBS, Chen K, Le W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Neuroimaging Initiative (ADNI). Neuroimage. 2009;in press
  6. Reiman EM, Chen K, Ayutyanont N, Lee W, Bandy D, Reschke C, et al. Twelve-month cerebral metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment: preliminary findings from the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2008;4:T58
  7. Mohs RC, Cohen L. Alzheimer's disease assessment scale. Psychopharmacol Bull. 1988;24:627–628
  8. Shaw LM, Vanderstichele H, Clark CM, Aisen PS, Petersen RC, Blennow K, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging subjects. Ann Neurol. 2009 March 18;[Epublication ahead of print]
  9. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–746

 The views stated here represent those of R.G.K., and do not represent an official statement of the United States Food and Drug Administration.

PII: S1552-5260(09)00057-0

doi: 10.1016/j.jalz.2009.02.005

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 3 , Pages 271-275 , May 2009

Article Tools